References
- BeattieKPhadkeGNovakovicJChapter four – carvedilolHarryGBProfiles of Drug Substances, Excipients and Related MethodologyCambridgeAcademic Press2013113157
- StanleyAJDicksonSHayesPCMulticentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleedingJ Hepatol20146151014101924953021
- ZhouS-FPolymorphism of human cytochrome P450 2D6 and its clinical significanceClin Pharmacokinet2009481276180419902987
- GiessmannTModessCHeckerUCYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjectsClin Pharmacol Ther200475321322215001973
- PanP-PWengQ-HZhouC-JThe role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitroEur J Drug Metab Pharmacokinet20144111825297456
- ShihmanterRNulmanIGolandSVariation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failureJ Clin Pharm Ther201439443243824673480
- Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacol Ther2007116349652618001838
- Ingelman-SundbergMPharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends Pharmacol Sci200425419320015063083
- ZangerUMRaimundoSEichelbaumMCytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistryNaunyn Schmiedebergs Arch Pharmacol20043691233714618296
- WangBYangLPZhangXZHuangSQBartlamMZhouSFNew insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzymeDrug Metab Rev200941457364319645588
- LiQWangRGuoYWenSXuLWangSRelationship of CYP2D6 genetic polymorphisms and the pharmacokinetics of tramadol in Chinese volunteersJ Clin Pharm Ther201035223924720456744
- DoradoPHerasNMachínEHernándezFTeranELlerenaACYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian populationEur J Clin Pharmacol201268563764422083166
- LlerenaADoradoPPeñas-LledóEMPharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacityPharmacogenomics2009101172819102711
- Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
- ZhouS-FLiuJ-PChowbayBPolymorphism of human cytochrome P450 enzymes and its clinical impactDrug Metab Rev20094128929519514967
- CaiJDaiDPGengPWEffects of 22 novel CYP2D6 variants found in the Chinese population on the bufuralol and dextromethorphan metabolisms in vitroBasic Clin Pharmacol Toxicol2016118319019926310775
- OldhamHGClarkeSEIn vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(−)-carvedilolDrug Metab Dispos19972589709779280405
- SaruwatariJNakashimaHTsuchimineSNishimuraMOgusuNYasui-FurukoriNPossible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disordersPharmgenomics Pers Med2014712112724868171
- TehLKBertilssonLPharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importanceDrug Metab Pharmacokinet2012271556722185816
- JohanssonIOscarsonMYueQYBertilssonLSjöqvistFIngelman-SundbergMGenetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylationMol Pharmacol19944634524597935325
- RowlandPBlaneyFESmythMGCrystal structure of human cytochrome P450 2D6J Biol Chem2006281117614762216352597
- QianJCXuXMHuGXGenetic variations of human CYP2D6 in the Chinese Han populationPharmacogenomics201314141731174324192122
- GuengerichFPHannaIHMartinMVGillamEMRole of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysisBiochemistry20034251245125312564927